Dexcom topped Wall Street’s expectations for third-quarter earnings, and the company nudged up its guidance for the remainder ...

Dexcom G7 15 Day arrives in Canada in November with longer sensor wear and expanded insurance coverage. Here's what users ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

DexCom (NasdaqGS:DXCM) reported that results from the CONNECT randomized controlled trial of its G7 CGM were published in The ...

Dexcom G7 15 Day continuous glucose monitoring (CGM) system will be available in Canada beginning in November for adults aged 18 and older living w ...

DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read why DXCM stock is a Buy.

DexCom, Inc. announced that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes.

DexCom, Inc. DXCM recently announced that results from its CONNECT randomized controlled trial have been published in The New England Journal of Medicine. The study evaluated the benefits of its ...

(NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose ...